News
- Author:
- Bruce Jancin
Publish date: January 3, 2020
SAN ANTONIO – The new clinical decision support tool can be used to sway payers to authorize earlier use of ustekinumab.
News
- Author:
- Bruce Jancin
Publish date: January 2, 2020
SAN ANTONIO – The new clinical decision support tool can be used to sway payers to authorize earlier use of ustekinumab.
News
- Author:
- Bruce Jancin
Publish date: December 30, 2019
MADRID – “The absolute risk is low, but it’s real.”
News
- Author:
- Bruce Jancin
Publish date: December 24, 2019
MADRID – Pediatric atopic dermatitis risk varies according to type of parental history of atopic disease.
News
- Author:
- Bruce Jancin
Publish date: December 20, 2019
SAN ANTONIO – Restoring the altered gut microbiota in patients with IBS pays off in reduced abnormal stools, pain, and bloating.
News
- Author:
- Bruce Jancin
Publish date: December 19, 2019
SAN ANTONIO – “We propose that biofeedback be given strong consideration as first-line therapy for this population, in whom overall we’re trying to...
News
- Author:
- Bruce Jancin
Publish date: December 16, 2019
SAN ANTONIO – The CTS5 prognostic score is strongly predictive of risk of late distant recurrence of breast cancer in patients over age 50 at initi...
News
- Author:
- Bruce Jancin
Publish date: December 13, 2019
SAN ANTONIO – Combining a CDK4/6 inhibitor with an aromatase inhibitor successfully downstages disease before surgery.
News
- Author:
- Bruce Jancin
Publish date: December 12, 2019
SAN ANTONIO – In the HER2CLIMB trial of women with heavily pretreated HER2-positive metastatic breast cancer, the 2-year estimated overall survival...
News
- Author:
- Bruce Jancin
Publish date: December 10, 2019
SAN ANTONIO – Know the risk factors for progression of mild Crohn’s disease.
News
- Author:
- Bruce Jancin
Publish date: December 10, 2019
SAN ANTONIO – American Cancer Society recommendation to lower starting age for colorectal cancer screening receives new support from a U.S. populat...
News
- Author:
- Bruce Jancin
Publish date: December 9, 2019
MADRID – Definitive evidence of the drug’s efficacy and safety must await the results of the pivotal phase 3 PEGASUS trial.
News
- Author:
- Bruce Jancin
Publish date: December 9, 2019
SAN ANTONIO – “I see this as we’re standing at the same place now as we were standing with Helicobacter pylori 30 years ago.” – Dr. David ...
News
- Author:
- Bruce Jancin
Publish date: December 4, 2019
SAN ANTONIO – New NASH drugs will transform clinical practice.
News
- Author:
- Bruce Jancin
Publish date: December 3, 2019
SAN ANTONIO – Meta-analysis documents high clinical success rate with favorable safety profile.
